X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
female (19) 19
middle aged (18) 18
oncology (17) 17
aged (14) 14
male (14) 14
adult (13) 13
index medicus (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
drug resistance (8) 8
aged, 80 and over (7) 7
chemotherapy (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cell line (6) 6
adolescent (5) 5
animals (5) 5
breast neoplasms - drug therapy (5) 5
cancer (5) 5
care and treatment (5) 5
research (5) 5
drug administration schedule (4) 4
treatment outcome (4) 4
antibodies, monoclonal, humanized - administration & dosage (3) 3
aromatase inhibitors (3) 3
base sequence (3) 3
bevacizumab (3) 3
breast neoplasms - pathology (3) 3
carcinoma - drug therapy (3) 3
combined modality therapy (3) 3
disease-free survival (3) 3
doxorubicin (3) 3
doxorubicin - adverse effects (3) 3
hematology, oncology and palliative medicine (3) 3
hodgkin disease - drug therapy (3) 3
imidazoles - therapeutic use (3) 3
karyotyping (3) 3
lomustine - adverse effects (3) 3
medicine, general & internal (3) 3
metastasis (3) 3
mice (3) 3
molecular sequence data (3) 3
neoplasm metastasis (3) 3
paclitaxel (3) 3
patients (3) 3
survival analysis (3) 3
therapy (3) 3
tumor cells, cultured (3) 3
tumors (3) 3
vinblastine - administration & dosage (3) 3
zoledronic acid (3) 3
amino acid sequence (2) 2
analysis (2) 2
anastrozole (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antigens, neoplasm (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
atp-binding cassette, sub-family b, member 1 (2) 2
bleomycin - administration & dosage (2) 2
bleomycin - adverse effects (2) 2
bone density - drug effects (2) 2
bone density conservation agents - administration & dosage (2) 2
bone neoplasms - secondary (2) 2
bone resorption (2) 2
breast cancer (2) 2
breast neoplasm (2) 2
breast neoplasms - mortality (2) 2
cancer therapies (2) 2
chemotherapy, adjuvant (2) 2
cisplatin - administration & dosage (2) 2
clinical trials (2) 2
dacarbazine - administration & dosage (2) 2
dacarbazine - adverse effects (2) 2
diphosphonates - administration & dosage (2) 2
diphosphonates - therapeutic use (2) 2
diseases (2) 2
dna topoisomerases, type ii - biosynthesis (2) 2
dna topoisomerases, type ii - metabolism (2) 2
dna-binding proteins (2) 2
docetaxel (2) 2
dose-response relationship, drug (2) 2
double-blind method (2) 2
doxorubicin - administration & dosage (2) 2
drosophila-melanogaster (2) 2
drug therapy (2) 2
erbb-2 protein (2) 2
follow-up (2) 2
follow-up studies (2) 2
health aspects (2) 2
heart diseases - chemically induced (2) 2
hydrophilic carboxyl-terminus (2) 2
identification (2) 2
imidazoles - administration & dosage (2) 2
infusions, intravenous (2) 2
isoenzymes - biosynthesis (2) 2
isoenzymes - metabolism (2) 2
leukemia - pathology (2) 2
lomustine - administration & dosage (2) 2
lung diseases - chemically induced (2) 2
mechlorethamine - administration & dosage (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 03/2012, Volume 118, Issue 5, pp. 1192 - 1201
Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures. Zoledronic acid... 
breast neoplasm | aromatase inhibitors | postmenopause | zoledronic acid | bone resorption | Osteoporosis, Postmenopausal - epidemiology | Bone and Bones - pathology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Follow-Up Studies | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Imidazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Bone and Bones - drug effects | Nitriles - administration & dosage | Carcinoma - complications | Antineoplastic Agents - adverse effects | Aged, 80 and over | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Osteoporosis, Postmenopausal - prevention & control | Triazoles - therapeutic use | Carcinoma - drug therapy | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Breast Neoplasms - drug therapy | Breast Neoplasms - complications | Bone Density - drug effects | Organ Size - drug effects | Algorithms | Osteoporosis, Postmenopausal - chemically induced | Aged | Nitriles - adverse effects | Nitriles - therapeutic use | Bone resorption | Care and treatment | Usage | Menopause | Zoledronic acid | Dosage and administration | Drug therapy
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 03/2012, Volume 118, Issue 5, pp. 1192 - 1201
BACKGROUND: Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures.... 
breast neoplasm | aromatase inhibitors | postmenopause | zoledronic acid | bone resorption | RECEIVING ADJUVANT LETROZOLE | BONE-MINERAL DENSITY | TAMOXIFEN | DOXORUBICIN | FOLLOW-UP | ANASTROZOLE | THERAPY | ONCOLOGY | EARLY BREAST-CANCER | POSTMENOPAUSAL WOMEN | PLUS ZOLEDRONIC ACID
Journal Article
by Mullane, MR and Mullane, Kathleen M and Morrison, VA and Morrison, Vicki A and Camacho, Luis H and Arvin, Ann and McNeil, S and McNeil, Shelly A and Durrand, Jessie and Campbell, Bernadette and Campbell, TC and Su, Shu-Chih and Chan, Ivan S F and Parrino, Janie and Kaplan, Susan S and Kaplan, HG and Popmihajlov, Zoran and Annunziato, Paula W and Cerana, S and Dictar, MO and Bonvehi, P and Tregnaghi, JP and Fein, L and Ashley, D and Singh, M and Singh, J and Hayes, T and Playford, G and Morrissey, O and Thaler, J and Kuehr, T and Greil, R and Pecherstorfer, M and Duck, L and Van Eygen, K and Aoun, M and De Prijck, B and Franke, FA and Barrios, CHE and Mendes, AVA and Serrano, SV and Garcia, RF and Moore, A and Moore, F and Camargo, JFC and Pires, LA and Alves, RS and Radinov, A and Oreshkov, K and Minchev, V and Hubenova, AI and Koynova, T and Ivanov, I and Rabotilova, B and Petrov, PA and Chilingirov, P and Karanikolov, S and Raynov, J and Grimard, D and Kumar, D and Larratt, LM and Weiss, K and Weiss, R and Delage, R and Diaz-Mitoma, FJ and Cano, PO and Couture, F and Carvajal, P and Yepes, A and Torres Ulloa, R and Fardella, P and Caglevic, C and Rojas, CA and Rojas, C and Orellana, E and Gonzalez, P and Gonzalez, ME and Acevedo, A and Galvez, KM and Franco, S and Restrepo, JG and Bonilla, C and Florez, LE and Ospina, AV and Manneh, R and Zorica, R and Vrdoljak, DV and Samarzija, M and Petruzelka, L and Vydra, J and Mayer, J and Cibula, D and Prausova, J and Paulson, G and Ontaneda, M and Palk, K and Vahlberg, A and Rooneem, R and Galtier, F and Postil, D and ... and V212 Protocol 011 Trial Team
The Lancet Infectious Diseases, ISSN 1473-3099, 09/2019, Volume 19, Issue 9, pp. 1001 - 1012
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 2012, Volume 11, Issue 2, pp. 101 - 111
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 09/1985, Volume 45, Issue 9, pp. 4091 - 4096
The emergence of drug-resistant tumor cells is a major limiting factor in cancer chemotherapy. There is little information about the nature of such resistant... 
Cell Line | Colchicine - pharmacology | Humans | Sarcoma - drug therapy | Membrane Proteins - analysis | Sarcoma - metabolism | Karyotyping | Doxorubicin - metabolism | Daunorubicin - metabolism | Glycoproteins - analysis | Sarcoma - genetics | Doxorubicin - pharmacology | Drug Resistance | Carbon Radioisotopes
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 08/1989, Volume 49, Issue 16, pp. 4542 - 4549
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 1989, Volume 49, Issue 16, pp. 4542 - 4549
Journal Article